PMN
insider transactionsProMIS Neurosciences Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 4 different insiders made open-market purchases in the last 365 days, totalling $8.7M.
Net shares · 365d
+1.4M
1.4M buy · 0 sell
Net value · 365d
$8.7M
$8.7M in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
8
1.4M buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
5.5K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
5.5K sh
Own New
-
Grant·A
Neil K Warma KEY
Chief Executive Officer
$0
160.0K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
5.5K sh
Own New
-
Grant·A
Principal Accounting Officer
$0
18.2K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
5.5K sh
Own New
-
Grant·A
Chief Development Officer
$0
50.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
50.0K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
5.5K sh
Own New
-
Buy·P
Director
$45.3K
4.0K sh · $11.33
Own +613%
-
Buy·P
Director
$48.8K
2.0K sh · $24.40
Own +19%
-
Buy·P
Director
$48.0K
2.0K sh · $24.00
Own +24%
-
Buy·P
Director
$21.9K
1.0K sh · $21.89
Own +14%
-
Buy·P
Director
$22.5K
1.0K sh · $22.53
Own +16%
-
Buy·P
Chief Development Officer
$25.0K
1.6K sh · $15.35
Own +70%
-
Grant·A
Neil K Warma KEY
Chief Executive Officer
—
6.2K sh
Own New
-
Grant·A
Neil K Warma KEY
Chief Executive Officer
$75.0K
6.2K sh · $12.13
Own New
-
Grant·A
Other
—
6.6K sh
Own New
-
Grant·A
Other
$80.0K
6.6K sh · $12.13
Own +364%
-
Grant·A
Director
—
3.0K sh
Own New
-
Grant·A
Director
$37.0K
3.0K sh · $12.13
Own +146%
-
Grant·A
Chief Development Officer
—
2.1K sh
Own New
-
Grant·A
Chief Development Officer
$25.0K
2.1K sh · $12.13
Own +817%
-
Grant·A
Chief Scientific Officer
—
4.1K sh
Own New
-
Grant·A
Chief Scientific Officer
$50.0K
4.1K sh · $12.13
Own New
-
Buy·P
—
700.7K sh
Own New
-
Buy·P
$8.5M
700.7K sh · $12.13
Own +289%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | William W Wyman | Grant A | 11.0K | $0 |
| May 20, 2026 | William W Wyman | Grant A | 5.5K | $0 |
| May 20, 2026 | Eugene Williams | Grant A | 11.0K | $0 |
| May 20, 2026 | Eugene Williams | Grant A | 5.5K | $0 |
| May 20, 2026 | Neil K Warma KEY | Grant A | 160.0K | $0 |
| May 20, 2026 | Madge K. Shafmaster | Grant A | 11.0K | $0 |
| May 20, 2026 | Madge K. Shafmaster | Grant A | 5.5K | $0 |
| May 20, 2026 | Max A. Milbury | Grant A | 18.2K | $0 |
| May 20, 2026 | Josh Mandel-Brehm | Grant A | 11.0K | $0 |
| May 20, 2026 | Josh Mandel-Brehm | Grant A | 5.5K | $0 |
| May 20, 2026 | Johanne Kaplan | Grant A | 50.0K | $0 |
| May 20, 2026 | Neil Cashman | Grant A | 50.0K | $0 |
| May 20, 2026 | Slanix Paul Alex | Grant A | 11.0K | $0 |
| May 20, 2026 | Slanix Paul Alex | Grant A | 5.5K | $0 |
| Apr 22, 2026 | Patrick D. Kirwin | Buy P | 4.0K | $45.3K |
| Mar 5, 2026 | Eugene Williams | Buy P | 2.0K | $48.8K |
| Mar 4, 2026 | Eugene Williams | Buy P | 2.0K | $48.0K |
| Mar 3, 2026 | Eugene Williams | Buy P | 1.0K | $21.9K |
| Mar 2, 2026 | Eugene Williams | Buy P | 1.0K | $22.5K |
| Feb 19, 2026 | Johanne Kaplan | Buy P | 1.6K | $25.0K |
| Feb 3, 2026 | Neil K Warma KEY | Grant A | 6.2K | — |
| Feb 3, 2026 | Neil K Warma KEY | Grant A | 6.2K | $75.0K |
| Feb 3, 2026 | Max A. Milbury | Grant A | 6.6K | — |
| Feb 3, 2026 | Max A. Milbury | Grant A | 6.6K | $80.0K |
| Feb 3, 2026 | Patrick D. Kirwin | Grant A | 3.0K | — |
| Feb 3, 2026 | Patrick D. Kirwin | Grant A | 3.0K | $37.0K |
| Feb 3, 2026 | Johanne Kaplan | Grant A | 2.1K | — |
| Feb 3, 2026 | Johanne Kaplan | Grant A | 2.1K | $25.0K |
| Feb 3, 2026 | Neil Cashman | Grant A | 4.1K | — |
| Feb 3, 2026 | Neil Cashman | Grant A | 4.1K | $50.0K |
| Feb 3, 2026 | ABG Management Ltd. / Ally Bridge MedAlpha Master Fund L.P. / Ally Bridge Group (NY) LLC / Yu Fan / Slanix Paul Alex | Buy P | 700.7K | — |
| Feb 3, 2026 | ABG Management Ltd. / Ally Bridge MedAlpha Master Fund L.P. / Ally Bridge Group (NY) LLC / Yu Fan / Slanix Paul Alex | Buy P | 700.7K | $8.5M |
About PMN insider trading
This page tracks insider transactions for ProMIS Neurosciences Inc. (PMN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.